Skip to main content

Anti-Cancer Drug Design is now published as Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.

Publisher: Cognizant Communication Corporation

Volume 15, Number 1, 2000

Favourites:
ADD

PKC412 - a protein kinase inhibitor with a broad therapeutic potential
pp. 17-28(12)
Authors: Fabbro, D; Ruetz, S; Bodis, S; Pruschy, M; Csermak, K; Man, A; Campochiaro, P; Wood, J; O'Reilly, T; Meyer, T

Favourites:
ADD

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
pp. 29-41(13)
Authors: Mendel, DB; Laird, AD; Smolich, BD; Blake, RA; Liang, C; Hannah, AL; Shaheen, RM; Ellis, LM; Weitman, S; Shawver, LK; Cherrington, JM

Favourites:
ADD

Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition
pp. 53-66(14)
Authors: Gussio, R; Zaharevitz, DW; McGrath, CF; Pattabiraman, N; Kellog, GE; Schultz, C; Link, A; Kunick, C; Leost, M; Meijer, L; Sausville, EA

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more